

Financial news for ENZY dated on 2018-01-11: Enzymotec Shares Halted With Code 'T12'; On Dec. 11, Co Shareholders Approved Purchase By Frutarom

Financial news for ENZY dated on 2017-12-11: Enzymotec Reports Holders Have Approved Purchase By Frutarom

Financial news for ENZY dated on 2017-11-15: Enzymotec Reports Q3 EPS \$0.07 vs \$0.08 Est., Sales \$19.46M vs \$14.3M Est.

Financial news for ENZY dated on 2017-08-30: Enzymotec Ltd. Expands VAYA Product Portfolio with 5 Nutritional Supplements Acquired from Union Springs Healthcare For \$3.6M As Well As Warrants To Purchase 200K Shares; Union Springs Will Receive Single Digit Royalty and Could Earn \$22M In Milestone Pay

Financial news for ENZY dated on 2017-08-28: Enzymotec Responds To Unsolicited Proposal From Frutarom To Acquire Co. For \$11.50/Share By Sending Letter To Frutarom CEO Ori Yehudai

Financial news for ENZY dated on 2017-08-28: Enzymotec Ltd. Responds to Unsolicited Proposal from Frutarom Ltd. for \$11.50/Share, Says Disappointed There Was Not an Attempt to Engage with Management

Financial news for ENZY dated on 2017-08-24: Amended 13D Filing From Frutarom On Enzymotec Shows 19.13% Stake

Financial news for ENZY dated on 2017-08-23: Notable Block Trade After-Hours In Enzymotec; 2.1M Shares At \$11.50

Financial news for ENZY dated on 2017-08-16: Enzymotec Reports Q2 Adj. EPS \$(0.06) vs \$0.05 Est., Sales \$13M vs \$12.78M Est.

Financial news for ENZY dated on 2017-07-06: Enzymotec Shares Halted On Circuit Breaker, Down 20%

Financial news for ENZY dated on 2017-06-28: Enzymotec Announces CFO Oren Bryan To Step Down

Financial news for ENZY dated on 2017-05-17: Enzymotec Reports Q1 Adj. EPS \$0.03 vs \$0.06 Est., Sales \$12M vs \$14.22M Est.

Financial news for ENZY dated on 2017-04-03: Neptune Technologies, Enzymotec Jointly Announce Entering Into of Broad Patent Corss-Licensing Deal; Enzymotec to Make One-Time Payment of \$1.63M to Neptune

Financial news for ENZY dated on 2017-03-09: Enzymotec Ltd. Names Erez Israeli CEO

Financial news for ENZY dated on 2017-02-22: Enzymotec Ltd. Reports Q4 Adj. EPS \$(0.10) vs. \$0.03 Est., Sales \$10.6M vs. \$11.47M

Financial news for ENZY dated on 2017-02-06: Enzymotec Reports Prelim. Q4 EPS \$(0.10) vs. Est. \$0.03, Rev. \$10.6M vs. Est. \$11.47M

Financial news for ENZY dated on 2016-11-17: Wells Fargo Downgrades Enzymotec Ltd. - Ordinary Shares to Market Perform

Financial news for ENZY dated on 2015-08-13: Wells Fargo Upgrades Enzymotec to Outperform

Financial news for ENZY dated on 2015-01-20: Enzymotec Ltd. Initiates Clinical Study of Vayacog in Mild Cognitive Impairment

Financial news for ENZY dated on 2014-11-13: Enzymotec Sees FY2014 EPS \$0.36-0.45

Financial news for ENZY dated on 2014-11-13: Enzymotec Reports Q3 EPS of \$0.05 vs \$0.04 Est; Revenue of \$9.50M vs \$10.22M Est

Financial news for ENZY dated on 2014-08-05: Enzymotec Sees FY2014 EPS \$0.34-0.43 vs \$0.81 Est

Financial news for ENZY dated on 2014-08-05: Enzymotec Reports Q2 EPS of \$0.02 Which May Not Compare \$0.10 Est

Financial news for ENZY dated on 2014-05-14: Enzymotec Sees FY2014 EPS \$0.64-0.94 vs \$0.86 Est

Financial news for ENZY dated on 2014-05-14: Enzymotec Reports Q1 EPS of \$0.24 vs \$0.17 Est; Revenue of \$17.90M vs \$19.40M Est

Financial news for ENZY dated on 2014-02-13: Enzymotec Reports Q4 EPS of \$0.15 vs

\$0.11 Est; Revenue of \$18.50M vs \$18.77M Est

Financial news for ENZY dated on 2014-02-03: Enzymotec Granted Patents for INFAT Uses in Canada and the US

Financial news for ENZY dated on 2013-12-11: Bank of America Downgrades Enzymotec to Underperform

Financial news for ENZY dated on 2013-11-11: Enzymotec Reports Q3 EPS of \$0.13 vs \$0.11 Est; Revenue of \$17.80M vs \$17.80M Est

Financial news for ENZY dated on 2013-10-22: Wells Fargo Initiates Coverage on Enzymotec at Outperform

Financial news for ENZY dated on 2013-10-22: Jefferies Initiates Coverage on Enzymotec at Hold, Announces \$19.00 PT

Financial news for ENZY dated on 2013-10-22: Canaccord Genuity Initiates Coverage on Enzymotec at Buy, Announces \$24.00 PT

Financial news for ENZY dated on 2013-10-22: Bank of America Initiates Coverage on Enzymotec at Buy, Announces \$21.00 PO

Financial news for ENZY dated on 2012-09-04: Enzymatics Names Jonathan DiVincenzo as President and CEO